The Transformation of CML Treatment and Care

Published on

Topics include: Treatments

Have there been new developments in chronic myelogenous leukemia (CML) treatment and care? Expert, Dr. Michael Deininger, discusses ongoing research, treatment side effect management, and the results of a 10-year study on survival rates and imatinib (Gleevec).  Dr. Deininger also sheds light on the accessibility of certain medicines, the importance of molecular testing, and how clinical trials show doctors and patients what is possible for the future of treatment.

View more programs featuring

Related Programs

ASH 2015 Coverage: Emerging Approaches for Treatment-Resistant CML Patients

At the 2015 ASH meeting, Carol Preston visited with CML expert Dr. Kathryn Kolibaba to discuss progress for CML patients who are Gleevec resistant.


A Changing Paradigm for CML Treatment

CML expert Dr. Giuseppe Saglio joined Patient Power to discuss the changing paradigm for CML treatment.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on September 22, 2017